Literature DB >> 10842707

Tabulation of transthyretin (TTR) variants as of 1/1/2000.

L H Connors1, A M Richardson, R Théberge, C E Costello.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10842707     DOI： 10.3109/13506120009146826

Source DB:  PubMed          Journal:  Amyloid        ISSN： 1350-6129            Impact factor:   7.141


× No keyword cloud information.
  19 in total

Review 1.  Technetium pyrophosphate myocardial uptake and peripheral neuropathy in a rare variant of familial transthyretin (TTR) amyloidosis (Ser23Asn): a case report and literature review.

Authors:  Adam Castaño; Sabahat Bokhari; Thomas H Brannagan; Julia Wynn; Mathew S Maurer
Journal:  Amyloid       Date:  2011-12-08       Impact factor: 7.141

2.  Electron capture dissociation at low temperatures reveals selective dissociations.

Authors:  Romulus Mihalca; Anne J Kleinnijenhuis; Liam A McDonnell; Albert J R Heck; Ron M A Heeren
Journal:  J Am Soc Mass Spectrom       Date:  2004-12       Impact factor: 3.109

3.  Vitreous amyloidosis in alanine 71 transthyretin mutation.

Authors:  H J Zambarakji; D G Charteris; W Ayliffe; P J Luthert; F Schon; P N Hawkins
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

4.  The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis.

Authors:  X Jiang; J N Buxbaum; J W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

Review 5.  Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment.

Authors:  David C Seldin; John L Berk; Flora Sam; Vaishali Sanchorawala
Journal:  Heart Fail Clin       Date:  2011-05-20       Impact factor: 3.179

Review 6.  New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.

Authors:  Stefano Perlini; Roberta Mussinelli; Francesco Salinaro
Journal:  Curr Heart Fail Rep       Date:  2016-12

Review 7.  The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.

Authors:  Steven M Johnson; Stephen Connelly; Colleen Fearns; Evan T Powers; Jeffery W Kelly
Journal:  J Mol Biol       Date:  2012-01-05       Impact factor: 5.469

8.  Transthyretin Arg-83 mutation in vitreous amyloidosis.

Authors:  Ling-Yan Chen; Lin Lu; Yong-Hao Li; Hui Zhong; Wang Fang; Li Zhang; Weng-Lin Li
Journal:  Int J Ophthalmol       Date:  2011-06-18       Impact factor: 1.779

9.  Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.

Authors:  J Rui Rodrigues; Carlos J V Simões; Cândida G Silva; Rui M M Brito
Journal:  Protein Sci       Date:  2010-02       Impact factor: 6.725

10.  Identification of S-sulfonation and S-thiolation of a novel transthyretin Phe33Cys variant from a patient diagnosed with familial transthyretin amyloidosis.

Authors:  Amareth Lim; Tatiana Prokaeva; Mark E McComb; Lawreen H Connors; Martha Skinner; Catherine E Costello
Journal:  Protein Sci       Date:  2003-08       Impact factor: 6.725
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.